Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening.

Bioorganic & medicinal chemistry - 1 Feb 2020

Swalley Susanne E

Abstract excerpt

Over the last 20 years, there have been remarkably few FDA-approved first-in-class drugs for neurodegenerative diseases. Debilitating conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis have no effective disease-modifying therapeutics on the market, signifying an area of high unmet medical need where novel approaches are needed. Using a phenotypic screening approach, two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neurodegenerative Diseases

Share to Neurogenetic and Muscular Disorders Research

Share to Neuroprotective Agents

Share to Phenotype

Share to RNA Research and Splicing

Share to Small Molecule Libraries

Source

Identifiers

PMID: 31889605
DOI: 10.1016/j.bmc.2019.115239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening.PMID 31889605Read ↗

Phenotypic screens targeting neurodegenerative diseases.Semantic proximity Read ↗

A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease.Semantic proximity Read ↗

Neurodegenerative diseases: a hotbed for splicing defects and the potential therapiesSemantic proximity Read ↗

RNA-Targeting Splicing Modifiers: Drug Development and Screening AssaysSemantic proximity Read ↗

Antisense Drugs Make Sense for Neurological DiseasesSemantic proximity Read ↗

Oligonucleotide therapeutics in neurodegenerative diseasesSemantic proximity Read ↗

Back to the future with phenotypic screening.Semantic proximity Read ↗

Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular AtrophySemantic proximity Read ↗

Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.Semantic proximity Read ↗

Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms.Semantic proximity Read ↗

RNA splicing modulator induces peripheral neuropathy with increased neurofilament light chain levels via p53 signalingSemantic proximity Read ↗

SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.